CHARLES TOWN, W.Va., Jan. 16 /PRNewswire-FirstCall/ -- The US neuropathic pain market consists of 4.7 million patients, and is expected to grow to more than 6.1 million patients, and be valued at $5.1 billion in 2018.
David B. Phillips, Ph.D. reports "We have not experienced the same economic down turn as other businesses because our market is growing."
John Johnson, Marketing Manager, has increased the ability of the company to expand its sales department in a novel way. "We have provided our inside sales reps with a special VOIP phone to use at home that give them the same access to answering the phone as they have in the office. We pay them on a commission basis and that has given us more sales at less cost. I fully expect sales to move to $6 million in 2009."
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc (Pink Sheets: RBRM) is an emerging medical device manufacturer of innovative technologies founded by world renowned medical device inventor David B. Phillips, Ph.D. ReBuilder Medical's flagship product is its FDA registered ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery powered medical product that provides a new non-surgical treatment for diabetic peripheral neuropathy which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
More information on ReBuilder Medical and its neuropathy products can be found at: www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
|SOURCE ReBuilder Medical Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved